uniQure has secured U.S. Food and Drug Administration priority review for its experimental Huntington’s disease gene therapy ifezuntirgene inilparvovec, also known as AMT-130, with a regulatory decision targeted for May 1, 2027. The agency has accepted the company’s Biologics License Application under the accelerated approval pathway, marking a significant milestone for a treatment designed to slow progression of the inherited neurodegenerative disorder through a single neurosurgical administration. If approved, AMT-130 could become the first disease-modifying therapy for Huntington’s disease, a condition for which existing treatments primarily address symptoms rather than the underlying cause.
The application is supported by Phase 1/2 clinical findings suggesting slower neurological deterioration compared with patients from an external natural history database. However, the evidence comes from relatively small studies, and the most recent four-year analysis produced mixed statistical findings. The FDA is also considering an advisory committee meeting, while uniQure prepares a randomized confirmatory trial involving approximately 200 patients to evaluate long-term functional outcomes.
Why has the FDA granted priority review to uniQure’s AMT-130 Huntington’s disease gene therapy?
The FDA has formally accepted uniQure’s Biologics License Application for ifezuntirgene inilparvovec and assigned a Prescription Drug User Fee Act target action date of May 1, 2027. Priority review generally shortens the agency’s intended review period for applications involving treatments that may offer significant improvements in serious conditions.
The submission seeks accelerated approval, a regulatory pathway that may permit earlier authorization based on qualifying evidence reasonably likely to predict meaningful clinical benefit. This approach is particularly relevant for serious diseases with substantial unmet medical needs, although the FDA must determine whether the submitted evidence satisfies the applicable requirements.
In its acceptance letter, the agency indicated that it is tentatively planning to convene an advisory committee to discuss the application. Such meetings allow independent experts to evaluate clinical evidence, safety concerns and regulatory questions before the FDA reaches a decision.
A meeting date has not been finalized, and an advisory committee recommendation would not be binding on the agency. The May 2027 target is also a regulatory review deadline rather than a guarantee that approval will be granted.
Ifezuntirgene inilparvovec has previously received Breakthrough Therapy, Regenerative Medicine Advanced Therapy and Fast Track designations from the FDA. These recognitions support regulatory interaction and development but do not independently establish the treatment’s safety or effectiveness.
uniQure chief executive officer Matt Kapusta indicated that the company views the application acceptance as an important step toward addressing the lack of disease-modifying options for Huntington’s disease. He also emphasized continued preparation for the confirmatory study while the regulatory review proceeds.
What do the three-year and four-year AMT-130 clinical results reveal about disease progression?
The application relies primarily on previously reported 36-month findings from uniQure’s Phase 1/2 program, compared with a propensity score-matched external control group drawn from the Enroll-HD natural history database.
An earlier analysis reported approximately 75% slower disease progression on the composite Unified Huntington’s Disease Rating Scale among high-dose recipients compared with the external control population. This composite measure combines assessments of movement, cognition and functional ability.
Subsequent analyses incorporating additional patients produced encouraging results at the same 36-month time point. Among 15 high-dose participants, uniQure reported approximately 80% slower deterioration on the composite scale and 67% slower decline in Total Functional Capacity compared with an updated external control.
Total Functional Capacity evaluates patients’ ability to maintain everyday activities, including employment, financial management and independent living. Preserving these capabilities is particularly relevant because Huntington’s disease progressively affects mobility, cognition and independence.
However, the 48-month analysis introduced important uncertainty. Among 12 high-dose patients with available four-year assessments, the composite score indicated 44% slower progression compared with the updated external control, but the difference was not statistically significant, with a reported p-value of 0.144.
At the same time, Total Functional Capacity showed approximately 61% slower deterioration, with a nominal p-value of 0.008. The company attributed some variability in the four-year findings to missing observations and potential survivor bias in the external comparison population.
These findings suggest possible sustained clinical activity, but the statistical inconsistency underscores the challenges of interpreting small, nonrandomized comparisons. The four-year results were reported after the original regulatory submission and were not included in the initial application dataset.
How does AMT-130 gene silencing target the underlying cause of Huntington’s disease?
Huntington’s disease is an inherited neurological disorder caused by an expanded CAG repeat sequence within the huntingtin gene. This genetic alteration leads to production of abnormal huntingtin protein, contributing to progressive damage in brain regions involved in movement, behavior and cognition.
Patients commonly develop involuntary movements, impaired coordination, psychiatric symptoms and declining cognitive function. Symptoms generally worsen over time, eventually affecting independence and the ability to perform routine activities.
AMT-130 uses an adeno-associated virus vector to deliver genetic instructions encoding a microRNA designed to reduce huntingtin gene expression. The treatment is intended to lower production of huntingtin protein, including potentially harmful fragments associated with disease pathology.
Unlike treatments that temporarily modify symptoms, AMT-130 seeks to influence the molecular process responsible for neurological deterioration. Its proposed therapeutic effect depends on sustained gene silencing after a single administration.
The procedure involves MRI-guided stereotactic neurosurgery, with the investigational therapy delivered directly into the striatum, including the caudate and putamen. These brain structures play central roles in motor control and are particularly affected by Huntington’s disease.
The targeted delivery approach is intended to achieve sufficient treatment exposure in relevant brain regions while limiting administration outside the central nervous system.
However, the procedure is substantially more invasive than oral or intravenous treatment. Surgical safety, treatment consistency and long-term effects of huntingtin suppression will therefore remain important components of the regulatory assessment.
Why does the planned 200-patient confirmatory trial matter for accelerated FDA approval?
uniQure and the FDA have aligned on important elements of a confirmatory study intended to provide stronger evidence of AMT-130’s clinical effects. The planned randomized trial will enroll approximately 200 patients with Huntington’s disease, assigning participants in a 2:1 ratio to receive AMT-130 or standard-of-care treatment.
Total Functional Capacity will serve as the primary endpoint at 36 months, allowing investigators to assess whether treatment preserves patients’ ability to perform daily activities over a prolonged period. The randomized design is important because the original application relies heavily on comparisons with an external natural history population. Although propensity score matching can reduce differences between treated patients and controls, it cannot eliminate all sources of selection bias or unmeasured confounding.
A contemporaneous comparison group should provide stronger evidence about whether observed differences result from treatment rather than variations in disease severity, clinical care or patient characteristics. uniQure plans to begin screening patients in the United States by the end of 2026. Management expects the study to be underway by the time a potential regulatory decision is reached.
If the FDA grants accelerated approval, continued clinical development and verification of benefit may remain necessary to maintain authorization. The agency could also require additional evidence before approving the treatment. The confirmatory study is therefore central to both the regulatory strategy and the long-term assessment of whether AMT-130 can meaningfully alter Huntington’s disease progression.
What safety and clinical uncertainties remain before AMT-130 can receive FDA approval?
Across its Phase 1/2 studies, uniQure has administered AMT-130 to 51 patients, including participants receiving different doses and treatment approaches. The U.S. randomized study included a sham-procedure control group, while the European program evaluated treatment in an open-label setting. Additional cohorts have investigated immunosuppression and treatment in patients with different brain-volume characteristics.
These studies have generated important information about procedural feasibility, tolerability and potential clinical activity. Nevertheless, the total treated population remains relatively small for evaluating uncommon adverse events or delayed complications.
Gene therapies delivered directly into the brain require particular attention to surgical risks, neurological complications, inflammation and potential long-term consequences of sustained protein suppression. The use of a viral vector also introduces considerations involving immune responses and the persistence of treatment activity over time. Unlike medicines administered repeatedly, the biological effects of a one-time gene therapy may be difficult to reverse.
The FDA must also assess manufacturing consistency, product quality and the reliability of neurosurgical administration. These factors are important because variation in delivery could influence treatment exposure and clinical outcomes. The encouraging functional findings must therefore be considered alongside uncertainty surrounding long-term safety and the limitations of the existing efficacy comparisons.
Could AMT-130 become the first disease-modifying Huntington’s disease treatment in 2027?
Approximately 75,000 people are estimated to be living with Huntington’s disease across the United States, European Union and United Kingdom, with substantially more individuals at risk of inheriting the condition. Current treatment approaches focus largely on controlling symptoms, including involuntary movements, behavioral difficulties and other complications. No therapy has been approved specifically to delay disease onset or slow the underlying progression.
A treatment capable of preserving neurological function could therefore represent an important advance, particularly if benefits persist after a single administration. However, AMT-130’s potential clinical role will depend on the FDA’s evaluation of its efficacy, safety, manufacturing and administration requirements. The agency must also determine whether evidence from external-control comparisons adequately supports accelerated approval.
The possibility of an advisory committee meeting introduces an additional milestone before the May 1, 2027 target decision. Expert discussion may focus on the interpretation of the three-year findings, statistical uncertainty in the four-year analysis and the adequacy of the planned confirmatory study.
For patients and families affected by Huntington’s disease, the priority review represents meaningful progress toward evaluating a treatment aimed at the underlying genetic cause. Nevertheless, regulatory acceptance is not the same as treatment approval, and the clinical evidence remains subject to substantial scrutiny.
The coming months will determine whether AMT-130 can advance from an experimental gene-silencing strategy toward the first approved disease-modifying treatment for Huntington’s disease. Until then, its long-term effectiveness and safety remain under investigation.
